Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1981 Jun;73(2):471–479. doi: 10.1111/j.1476-5381.1981.tb10445.x

The beneficial actions of bepridil in acute myocardial infarction in anaesthetized dogs.

R J Marshall, A W Muir
PMCID: PMC2071673  PMID: 6786404

Abstract

1 When administered intravenously shortly before acute coronary ligation in dogs anaesthetized with chloralose, bepridil (5 mg/kg) produced immediate and transient falls in coronary and systemic vascular resistance which were accompanied by marked decreases in myocardial oxygen extraction. These effects were followed by sustained decreases in heart rate and myocardial oxygen consumption. 2 This dose of bepridil reduced the number of premature ventricular beats and abolished fibrillation induced by coronary artery ligation without modifying the haemodynamic or metabolic consequences (lactate production) of myocardial ischaemia. 3 When administered 1.5-2 h after ligation, bepridil did not compromise the critical perfusion of the acutely ischaemic zone but reduced the lactate production and ST-segment elevation in the ischaemic zone. 4 These results suggest that bepridil may be a useful drug in the chronic treatment of angina pectoris and in this respect may possess advantages over beta-adrenoceptor antagonists.

Full text

PDF
471

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brooks W. W., Verrier R. L., Lown B. Protective effect of verapamil on vulnerability to ventricular fibrillation during myocardial ischaemia and reperfusion. Cardiovasc Res. 1980 May;14(5):295–302. doi: 10.1093/cvr/14.5.295. [DOI] [PubMed] [Google Scholar]
  2. Cosnier D., Duchenne-Marullaz P., Rispat G., Streichenberger G. Cardiovascular pharmacology of bepridil (1[3 isobutoxy 2 (benzylphenyl) amino] propyl pyrrolidine hydrochloride) a new potential anti-anginal compound. Arch Int Pharmacodyn Ther. 1977 Jan;225(1):133–151. [PubMed] [Google Scholar]
  3. Douglas I. R., MacDonald J. A., Milligan G. F., Mellon A., Ledingham I. M. A comparison of methods for the measurement of cardiac output and blood oxygen content. Br J Anaesth. 1975 Apr;47(4):443–450. doi: 10.1093/bja/47.4.443. [DOI] [PubMed] [Google Scholar]
  4. Elharrar V., Gaum W. E., Zipes D. P. Effect of drugs on conduction delay and incidence of ventricular arrhythmias induced by acute coronary occlusion in dogs. Am J Cardiol. 1977 Apr;39(4):544–549. doi: 10.1016/s0002-9149(77)80164-1. [DOI] [PubMed] [Google Scholar]
  5. Gross G. J., Winbury M. M. Beta adrenergic blockade on intramyocardial distribution of coronary blood flow. J Pharmacol Exp Ther. 1973 Dec;187(3):451–464. [PubMed] [Google Scholar]
  6. Kane K. A., Winslow E. Antidysrhythmic and electrophysiological effects of a new antianginal agent, bepridil. J Cardiovasc Pharmacol. 1980;2(2):193–203. doi: 10.1097/00005344-198003000-00010. [DOI] [PubMed] [Google Scholar]
  7. Kaumann A. J., Aramendía P. Prevention of ventricular fibrillation induced by coronary ligation. J Pharmacol Exp Ther. 1968 Dec;164(2):326–332. [PubMed] [Google Scholar]
  8. Labrid C., Grosset A., Dureng G., Mironneau J., Duchene-Marullaz P. Some membrane interactions with bepridil, a new antianginal agent. J Pharmacol Exp Ther. 1979 Dec;211(3):546–554. [PubMed] [Google Scholar]
  9. Ledingham I. M., Parratt J. R., Smith G., Vance J. P. Haemodynamic and myocardial effects of hyperbaric oxygen in dogs subjected to haemorrhage. Cardiovasc Res. 1971 Jul;5(3):277–285. doi: 10.1093/cvr/5.3.277. [DOI] [PubMed] [Google Scholar]
  10. Marhsall R. J., Parratt J. R. The effect of noradrenaline on blood flow and oxygen consumption in normal and ischemic areas of myocardium. Am Heart J. 1973 Nov;86(5):653–662. doi: 10.1016/0002-8703(73)90343-8. [DOI] [PubMed] [Google Scholar]
  11. Marshall R. J., Parratt J. R. Antiarrhythmic, haemodynamic and metabolic effects of 3alpha-amino-5alpha-androstan-2beta-ol-17-one hydrochloride in greyhounds following acute coronary artery ligation. Br J Pharmacol. 1975 Nov;55(3):359–368. doi: 10.1111/j.1476-5381.1975.tb06939.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Marshall R. J., Parratt J. R. Comparative effects of propranolol and practolol in the early stages of experimental canine myocardial infarction. Br J Pharmacol. 1976 Jun;57(2):295–303. doi: 10.1111/j.1476-5381.1976.tb07479.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Marshall R. J., Parratt J. R. Drug-induced changes in blood flow in the acutley ischaemic canine myocardium;relationship to subendocardial driving pressure. Clin Exp Pharmacol Physiol. 1974 Mar-Apr;1(2):99–112. doi: 10.1111/j.1440-1681.1974.tb00531.x. [DOI] [PubMed] [Google Scholar]
  14. Marshall R. J., Parratt J. R. The effects of disopyramide phosphate on early post-coronary artery ligation dysrhythmias and on epicardial ST-segment elevation in anaesthetized dogs. Br J Pharmacol. 1979 Jun;66(2):241–250. doi: 10.1111/j.1476-5381.1979.tb13672.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Marshall R. J., Parratt J. R. The haemodynamic and metabolic effects of MG 8926, a prospective antidysrhythmic and antianginal agent. Br J Pharmacol. 1977 Feb;59(2):311–322. doi: 10.1111/j.1476-5381.1977.tb07494.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Stein P. D., Marzilli M., Sabbah H. N., Lee T. Systolic and diastolic pressure gradients within the left ventricular wall. Am J Physiol. 1980 May;238(5):H625–H630. doi: 10.1152/ajpheart.1980.238.5.H625. [DOI] [PubMed] [Google Scholar]
  17. Vogel S., Crampton R., Sperelakis N. Blockade of myocardial slow channels by bepridil (CERM-1978). J Pharmacol Exp Ther. 1979 Sep;210(3):378–385. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES